All In MedTech

Device Trial Radar · NCT04763200

Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function: The PROTECT IV Trial

Last checked: Nov 20, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 1,252 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,252

Planned (sponsor's estimate)

Start

Apr 13, 2021

Primary completion

Oct 2026

Study completion Oct 2027

Sponsor

Lead sponsor
Abiomed Inc.Public (JNJ)
Sponsor type
Industry
First posted
Feb 21, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess if using the Impella® CP (or Impella® 2.5) device during high-risk PCI in patients with reduced left-sided heart function will result in an improvement in symptoms, heart function and health after a heart procedure compared to the current standard of care.

Conditions

  • Left Ventricular Dysfunction
  • Coronary Artery Disease

Interventions

  • Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®Device

    Impella CP / Impella CP with SmartAssist will be used in most patients randomized to the Impella arm. Impella 2.5 may be used in patients with small body size (BMI \<20 kg/m2 or body weight \<60 kg) or if the iliofemoral vasculature is able to accommodate the smaller Impella 2.5 device but not the Impella CP device.

  • IABP Intra-aortic balloon pumpDevice

    IABP uses counterpulsation to provide 0.2L/min coronary flow

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The composite of all-cause death, stroke, MI, unplanned clinically driven revascularization, durable LVAD implant or heart transplant, or other hospitalization for cardiovascular (CV) causes.Time frame: 3 years

Locations

110 sites in 7 countries. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama

  • St. Joseph's Medical Center - Phoenix

    Phoenix, Arizona

  • Northwest Medical Center Tucson

    Tucson, Arizona

107 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.